AstraZeneca PLC Digs Deeper in China With Generics Buy

AstraZeneca is stepping up its drive into emerging markets by buying a Chinese maker of generic injectable antibiotics. The move highlights the growing importance of markets like China for international drugmakers, even as healthcare reforms in the country lead to some slowing in recent rapid growth in demand for medicines. Britain's second biggest drugmaker said on Thursday it was buying privately owned Guangdong BeiKang Pharmaceutical for an undisclosed sum under a deal set to close in the first quarter of 2012.

Back to news